ArticleBMC urology2025
Investigation of androgen receptor expression in urothelial carcinoma of the bladder.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have demonstrated the importance of the androgen receptor (AR) in the development of bladder cancer and have proposed it as a potential biomarker or therapeutic hypothesis. However, the relationship between AR expression and both clinical features of patients and intrinsic tumor characteristics remains uncertain.
aimsTo evaluate the association between AR immunohistochemical expression and clinical as well as pathological characteristics of bladder cancer.
methodsWe conducted a retrospective cohort including patients diagnosed with bladder cancer through transurethral resection of the bladder (TURB) between 2016 and 2021. For each case, AR immunoexpression was tested and analyzed in relation to sex, age, smoking history, number of tumor foci, tumor size, vascular invasion, histological grade, carcinoma in situ, and pathological stage.
resultsLow AR expression was observed in 97.5% of cases, while high expression was identified in 1.4% and indeterminate cases accounted for 1.1% of the cohort. AR immunoexpression was not related to clinical or pathological variables.
conclusionNo significant associations were identified between AR expression and clinical or pathological variables, suggesting that its potential role as a biomarker in bladder cancer warrants further investigation. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.